Get started
Work

Management paradigms for chronic rhinosinusitis in individuals with asthma: An evidence‐based review with recommendations

Year: 2022
Type: review
Study design: Systematic Review
Abstract: BACKGROUND: Despite the significant morbidity associated with chronic rhinosinusitis (CRS) in individuals with asthma (CRSwA), there is a paucity of codified, evidence-based management strategies for CRS in this population. METHODS: Using PubMed, Embase, and Cochrane Review Databases, a systematic review was performed covering management strategies for CRSwA. A total of 5903 articles were screened, and 70 were included for full-text analysis. After application of exclusion criteria, 53 articles comprised the qualitative synthesis. The level of evidence was graded and benefit-harm assessments, as well as value judgment and recommendations, were provided RESULTS: Strong evidence confirms the benefit of oral and topical medications on sinonasal-specific outcomes in individuals with CRSwA; there is low-grade evidence demonstrating that these agents improve lung function and/or asthma control. Moderate to strong evidence suggests that endoscopic sinus surgery (ESS) improves both sinonasal- and asthma-specific quality of life. Although there is insufficient to low evidence to indicate that ESS improves pulmonary function in this population, data indicate a positive impact of this intervention on asthma control. Biologic medications strongly improve both subjective and objective sinonasal- and asthma-specific outcomes. CONCLUSION: Evidence supports managing CRS in individuals with CRSwA in a stepwise fashion, starting with traditional nonbiologic oral and topical medication, and escalating to second-line treatments, such as ESS and biologics. Optimal treatment of individuals who have CRSwA often requires concurrent, directed management of asthma, as not all CRS interventions impact asthma status.
DOI: 10.1002/alr.23130
Authors: Amarbir S. Gill, Jeremiah A. Alt, Kara Y. Detwiller, Nicholas R. Rowan, Stacey T. Gray, Peter W. Hellings, Shyam R. Joshi, Jivianne T. Lee, Zach M. Soler, Bruce K. Tan, Jennifer L. Taylor‐Cousar, Sarah K. Wise, Tara J. Wu, Daniel M. Beswick
Institutions: University of Michigan, University of Utah, Oregon Health & Science University, Johns Hopkins University, Johns Hopkins Medicine, Johns Hopkins Hospital, Massachusetts Eye and Ear Infirmary, Harvard University, Universitair Ziekenhuis Leuven, Ghent University, University of California, Los Angeles, Medical University of South Carolina, Northwestern University, National Jewish Health, Emory University
Language: English
Field: Medicine
Open Access status: bronze
Funders: Cystic Fibrosis Foundation, Sanofi, Stryker, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Insmed, National Institutes of Health, Genentech, National Institute on Deafness and Other Communication Disorders, National Institute of Allergy and Infectious Diseases
OpenAlex ID: W4313278387
FWCI: 0.786
Cites: 121
Cited by: 15
Related to: 10